典型文献
Safety and efficacy of Compound Huangdai Tablets combined with all-trans retinoic acid for treatment of acute promyelocytic leukemia:Clinical evidence and potential mechanisms
文献摘要：
Objective:To evaluate the safety and efficacy of Compound Huangdai Tablets(Realgar-Indigo Naturalis formula,RIF)combined with all-trans retinoic acid(ATRA)to treat acute promyelocytic leukemia(APL).Methods:This study was registered in PROSPERO(CRD42018108118).The relevant literatures on RIF treatment of APL were systematically searched in the following databases:China National Knowledge Infrastructure,Wanfang,VIP Medical Information System,Chinese Biomedical Database,EMBASE,Cochrane Library,and PubMed.The quality of the included studies was evaluated and Review Manager 5.3 software and Stata 13.0 software were used to perform the Meta-analysis.In addition,this study used the method of network pharmacology to conduct a preliminary exploration of the mechanism of RIF on APL.Results:The study included 12 studies involving 775 APL patients.The Meta-analysis showed that there was no significant difference(P＞0.05)between the RIF group and the arsenic trioxide(ATO)group for primary outcomes,secondary outcomes apart from liver dysfunction.The incidence of liver dysfunction(P=0.006)in the RIF group were significantly lower than those in the ATO group.In addition,the cost of maintenance therapy in the RIF group was significantly lower(P＜0.05)than the ATO group.Besides,the active ingredients in RIF mainly act on targets proteins such as ACHE,NCOA2,RXRA,and then play a role in the treatment of APL through regulating multiple molecular mechanisms,such as TP53 regulates tran-scription of cell cycle genes,nuclear receptor transcription pathway.Conclusion:There was no significant difference in efficacy of oral RIF combined with ATRA compared with intravenous ATO combined with ATRA for the treatment of APL.The oral RIF exposed patients to less risk,offered more convenience and had lower prices.RIF can treat APL by multi-target and multi-pathway interventions that inducing apoptosis of APL cells and inhibiting the proliferation of APL cells,and so on.Therefore,oral RIF in the treatment of APL is worthy of further research and development.
文献关键词：
中图分类号：
作者姓名：
Qianqian Huang;Tao Wang;Yan Xiong;Liping Qu;Qiaozhi Yin;Wenjun Zou
作者机构：
College of Pharmacy,Chengdu University of Traditional Chinese Medicine,Chengdu 611137,China;School of Medical and Life Sciences,Chengdu University of Traditional Chinese Medicine,Chengdu 610041,China
文献出处：
引用格式：
[1]Qianqian Huang;Tao Wang;Yan Xiong;Liping Qu;Qiaozhi Yin;Wenjun Zou-.Safety and efficacy of Compound Huangdai Tablets combined with all-trans retinoic acid for treatment of acute promyelocytic leukemia:Clinical evidence and potential mechanisms)[J].中草药（英文版）,2022(01):154-165
A类：
Huangdai,Naturalis,CRD42018108118
B类：
Safety,efficacy,Compound,Tablets,combined,retinoic,acid,treatment,acute,promyelocytic,leukemia,Clinical,evidence,potential,mechanisms,Objective,To,safety,Realgar,Indigo,formula,RIF,ATRA,APL,Methods,This,study,was,registered,PROSPERO,relevant,literatures,were,systematically,searched,following,databases,China,National,Knowledge,Infrastructure,Wanfang,VIP,Medical,Information,System,Chinese,Biomedical,Database,EMBASE,Cochrane,Library,quality,included,studies,evaluated,Review,Manager,software,Stata,used,perform,analysis,addition,this,method,network,pharmacology,conduct,preliminary,exploration,Results,involving,patients,showed,that,there,difference,between,group,arsenic,trioxide,ATO,primary,outcomes,secondary,apart,from,liver,dysfunction,incidence,significantly,lower,than,those,cost,maintenance,therapy,Besides,active,ingredients,mainly,targets,proteins,such,ACHE,NCOA2,RXRA,then,play,role,through,regulating,multiple,molecular,TP53,regulates,cycle,genes,nuclear,receptor,transcription,pathway,Conclusion,oral,compared,intravenous,exposed,less,risk,offered,more,convenience,had,prices,by,interventions,inducing,apoptosis,cells,inhibiting,proliferation,Therefore,worthy,further,research,development
AB值：
0.505894
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
